Get started
Author

Kent Yip

Observed names: K. Yip, K.P. Yip
ORCID: 0009-0001-5122-128X
Observed ORCID: 0009-0001-5122-128X
OpenAlex ID: A5035293640
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
2024 · Jean-Pascal Machiels, Yungan Tao, et al. · The Lancet Oncology · 288
Intensity modulated radiotherapy (IMRT) in the management of locally advanced oropharyngeal squamous cell carcinomata (SCC): disease control and functional outcome using the therapy outcome measure (TOM) score - report from a single U.K. institution
2010 · Charlotte J Ingle, Kent Yip, et al. · Head & Neck Oncology · 10
PDF
Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma — Introducing the PERM Trial
2018 · K. Yip, A. Melcher, et al. · Clinical Oncology · 6
979TiP POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status 2 with recurrent or metastatic squamous cell carcinoma of the head and neck
2020 · S. Forsyth, K. Yip, et al. · Annals of Oncology · 2
PDF
The Acute Physiological Effects of the Vaso-Active Drug, L-NNA, a Nitric Oxide Synthase Inhibitor, on Renal and Tumour Perfusion in Human Subjects
2014 · Kent Yip, Vicky Goh, et al. · Journal of Cancer Therapy · 2
PDF
Management of lung cancer in patients with interstitial lung disease
2020 · P. Verghese, K. Thippu Jayaprakash, et al. · Lung Cancer · 1
The Application of AI in Cancer MDT and its Legal Implication
2026 · K. Yip, H. Johnson, et al. · Clinical Oncology
Implementation of a regional lung radiotherapy protocol in the UK
2023 · Susan John, Michelle Bates, et al. · Lung Cancer
Harmonisation of radiotherapy practice in lung cancer: East of England Regional Radiotherapy Network Initiative
2022 · Huiqi Yang, Michelle Bates, et al. · Lung Cancer
Brigatinib experience on the ALK project
2019 · F. Gomes, N. Tokaca, et al. · Annals of Oncology
Implications for UK practice of the use of durvalumab in stage III NSCLC
2019 · M.S. Iqbal, P. Atherton, et al. · Annals of Oncology
Clinical presentation and prognosis of high PD-L1 expressors in non-small cell lung cancer
2019 · I.S. Chin, K.P. Yip, et al. · Lung Cancer
Real-world outcomes with pembrolizumab in patients with treatment-naive advanced/metastatic NSCLC in the UK: multicentre retrospective observational study
2019 · N. Tokaca, F. Gomes, et al. · Lung Cancer
P2.13-01 Brigatinib Use in England – Where Next?
2018 · F. Gomes, K. Yip, et al. · Journal of Thoracic Oncology
High incidence of brain metastases at presentation in patients with anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) in a large district general hospital
2018 · K.P. Yip, A. Chatterjee, et al. · Lung Cancer
P1.14-009 Comparison of Dosimetric Parameters and Outcome in Non-Small Cell Lung Cancer Patients Having 3D Conformal or VMAT Plans
2017 · N. Abdul Satar, S. Lynch, et al. · Journal of Thoracic Oncology
Survival outcomes after whole-brain radiotherapy for metastatic melanoma
2017 · D. Yang, K. Yip, et al. · Clinical Oncology
PD-0034: Feasibility of using multiparametric MRI to study the effect of brachytherapy catheter insertion into the prostate
2013 · K. Yip, U. Patel, et al. · Radiotherapy and Oncology
PO-0703: PROCON a phase Ib/II trial to evaluate concomitant carbogen & nicotinamide during prostate RT: early toxicity report
2013 · J. Valentine, K. Yip, et al. · Radiotherapy and Oncology
PD-0136: Hypoxia biomarkers for prognostic evaluation and the prediction of outcome following prostate radiotherapy
2013 · R. Alonzi, R. Smith, et al. · Radiotherapy and Oncology
PDF
A trial of PROstate radiotherapy in CONjunction with carbogen and nicotinamide (PROCON)
2012 · Kent Yip
Works count: 21
Citation count: 309
H-index: 3
I10-index: 2
Year
Topic
Type